XTX Topco Ltd Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

XTX Topco Ltd bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 16,805 shares of the company’s stock, valued at approximately $673,000.

Several other institutional investors have also recently made changes to their positions in the company. Great Point Partners LLC bought a new position in Ionis Pharmaceuticals in the second quarter worth $15,728,000. International Assets Investment Management LLC grew its holdings in Ionis Pharmaceuticals by 3,287.0% in the third quarter. International Assets Investment Management LLC now owns 328,772 shares of the company’s stock worth $13,171,000 after purchasing an additional 319,065 shares during the period. Logos Global Management LP purchased a new position in shares of Ionis Pharmaceuticals during the second quarter valued at approximately $14,298,000. Baker BROS. Advisors LP purchased a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth approximately $8,952,000. Finally, Marshall Wace LLP raised its stake in Ionis Pharmaceuticals by 1,021.5% during the second quarter. Marshall Wace LLP now owns 173,199 shares of the company’s stock valued at $8,255,000 after buying an additional 157,756 shares during the last quarter. Institutional investors own 93.86% of the company’s stock.

Wall Street Analysts Forecast Growth

IONS has been the topic of a number of analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Needham & Company LLC reissued a “buy” rating and issued a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. Piper Sandler reduced their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Guggenheim reduced their price target on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company cut their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $60.65.

Insider Buying and Selling

In other news, EVP Eric Swayze sold 1,194 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total value of $45,276.48. Following the transaction, the executive vice president now owns 33,713 shares of the company’s stock, valued at approximately $1,278,396.96. The trade was a 3.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brett P. Monia sold 6,630 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $38.05, for a total transaction of $252,271.50. Following the transaction, the chief executive officer now directly owns 167,393 shares of the company’s stock, valued at $6,369,303.65. The trade was a 3.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,877 shares of company stock worth $299,578. 2.71% of the stock is owned by corporate insiders.

Ionis Pharmaceuticals Trading Down 2.6 %

Shares of Ionis Pharmaceuticals stock opened at $37.01 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. The company has a fifty day moving average of $37.54 and a 200 day moving average of $42.29. The company has a market capitalization of $5.84 billion, a P/E ratio of -15.17 and a beta of 0.35. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $33.33 and a fifty-two week high of $54.44.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.